NEXGEL, Inc. (NXGLW) stock analysis

From the 10-K filed 2026-03-31

How it makes money

It produces electron beam cross-linked hydrogels, generating revenue through bulk roll stock for third parties and finished goods for its own consumer brands.

Profit is driven by the manufacturing of custom gels that meet rigid tolerance specifications for thickness, water content, and absorption. It operates as a contract manufacturer for bulk rolls and a direct-to-consumer brand owner.

The business model leverages a transition toward finished goods and white labeling, where it provides completed products to OTC brands rather than just components, increasing its share of the value chain.

What protects it: the moat

It utilizes proprietary electron beam cross-linking technology that avoids chemical agents, operating one of only two facilities capable of producing these specific transdermal products.

Management claims its competitive advantage lies in a manufacturing process that requires no chemical cross-linking agents, making the resulting patches gentler for skin applications.

Entry barriers are reinforced by an FDA-registered 13,500 square foot facility that can produce 1.4 billion square inches of product annually, which is currently operating at only 15% to 20% capacity.

What growth costs

Maintaining 16,500 square feet of FDA-compliant space and funding $2 thousand in research costs supports the transition into finished medical device licensing.

The company is pursuing a consumer product roll-up strategy through acquisitions like Silly George. It must maintain specialized facilities in Pennsylvania and Texas to meet stringent FDA Quality System Regulations.

Growth requires spending on 510(k) premarket submissions for new devices like NEXDrape and NEXDerm, though it intends to find licensing partners rather than commercializing these devices independently.

What could damage it

Because it operates without long-term customer contracts on a purchase order basis, the company must cover fixed facility costs even during sudden order disruptions.

A lack of minimum purchase commitments means revenue can vanish instantly while facility leases and regulatory compliance costs remain fixed. This risk is compounded by a heavy reliance on Amazon and Shopify for consumer distribution.

If these digital marketplaces terminate their relationship or experience disruptions, the company loses its primary channel to reach end consumers for its branded product lines.

About NEXGEL, Inc.

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.